Substitute form 1449A/PTO	Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	10/049,727
	Filing Date	June 25, 2002
	First Named Inventor	Yahia Gawad
	Group Art Unit	1645
(use as many sheets as necessary)	Examiner Name	Unknown
Sheet 1 of 1	Attorney Docket Number	3477-93

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document: Office	Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
CA	1	WO	WO 97/39028		American National Red Cross	10/23/1997		
CA	2	WO	WO 98/16643		Human Genome Sciences	04/23/1998		

RECEIVED
AUG 1 6 2002
TECH CENTER 1600/2900

OIPE AUG 1 3 2002 PATENT & TRADEMARK OFFICE

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T
CA	3	International Search Report, PCT/CA00/00464, November 8, 2000	
CA	4	Seiffert, *The Glycosaminoglycan Binding Site Governs Ligand Binding to the Somatomedin B. Domain of Vitronectin*, The Journal of Biological Chemistry, Vol. 272, No. 15, April 11, 1997, pp. 9971-9978	
CA	5	Lawrence et al., *Characterization of the Binding of Different Conformational Forms of Plasminogen Activator Inhibitor-1 to Vitronectin*, The Journal of Biological Chemistry, Vol. 272, No. 12, March 21, 1997, pp. 7676-7680	
CA	6	Lawrence et al., *Localization of Vitronectin Binding Domain in Plasminogen Activator Inhibitor-1*, The Journal of Biological Chemistry, Vol. 269, No. 21, May 27, 1994, pp. 15223-15228	
CA	7	Kost et al., *Mapping of Binding Sites for Heparin, Plasminogen Activator Inhibitor-1, and Plasminogen to Vitronectin's Heparin-binding Region Reveals a Novel Vitronectin-dependent Feedback Mechanism for the Control of Plasmin Formation*, The Journal of Biological Chemistry, Vol. 267, NO. 17, June 15, 1992, pp. 12098-12105	
CA	8	Declerck et al., *Purification and Characterization of a Plasminogen Activator Inhibitor 1 Binding Protein from Human Plasma*, The Journal of Biological Chemistry, Vol. 263, No. 30, October 25, 1988, pp. 15454-15461	

COPY OF PAPERS
ORIGINALLY FILED

Examiner Signature	CA	Date Considered	12/28/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of

Complet if Known	
Application Number	10/049,727
Filing Date	06/25/2002
First Named Inventor	Yahia Gawad
Group Art Unit	1641
Examiner Name	Gailene Gabel
Attorney Docket Number	3477-931

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	U.S. Patent Document Number	U.S. Patent Document Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	5,629,160		Loskutoff et al.	05/13/1997	
	2	5,472,851		Pussard née Constant et al.	12/05/1995	
	3	5,422,245		Nielsen et al.	06/06/95	
	4	5,352,583		Sakata et al.	10/04/1994	
	5	5,102,787		Sasamata et al.	04/07/1992	
	6	4,563,420		Verheijen et al.	01/07/1986	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T
	7	Friederich et al., *Novel Low-Molecular-Weight Inhibitor of PAI-1 (XR5118) Promotes Endogenous Fibrinolysis and Reduces Postthrombolysis Thrombus Growth in Rabbits*, Circulation, Vol. 96, No. 3, August 5, 1997, pp. 916-921	
	8	Ohtani et al., *T-686, A Novel Inhibitor of Plasminogen Activator Inhibitor-1, Inhibits Thrombosis Without Impairment of Hemostasis in Rats*, European Journal of Pharmacology, Vol. 330, 1997, pp. 151-156.	
	9	Nordenhem et al., *Plasminogen Activator Inhibitor-1 (PAI-1) Content in Platelets from Healthy Individuals Genotyped for the 4G/5G Polymorphism in the PAI-1 Gene*, Scand J. Clin Lab Invest, Vol. 57, 1997, pp. 453-462.	
	10	Lang et al., *Calcium-Dependent Stabilization of Type I Plasminogen Activator Inhibitor Within Platelet α-Granules*, The Journal of Biological Chemistry, Vol. 271, February 2, 1996, pp. 2754-2761	
	11	Sakata et al., *Impaired Fibrinolysis Early After Percutaneous Transluminal Coronary Angioplasty Is Associated With Restenosis*, American Hear Journal, Vol. 131, No. 1, January 1996, pp. 1-6	
	12	Eitzman et al., *Peptide-Mediated Inactivation of Recombinant and Platelet Plasminogen Activator Inhibitor-1 In Vitro*, J. Clin. Invest., Vol. 95, May 1995, pp. 2416-2420	
	13	Nieuwenhuizen et al., *An Enzyme Immunoassay for the Simultaneous Determination of Active Type-1 Plasminogen Activator Inhibitor (PAI-1), and t-PA/PAI-1 Complexes*, Blood Coagulation and Fibrinolysis, Vol. 6, 1995, pp. 520-526	
	14	Kurnik, *Circadian Variation in the Efficacy of Tissue-Type Plasminogen Activator*, Circulation, Vol. 9, No. 5, pp. 1341-1346	
	15	Hara et al., *Plasma Plasminogen Activator Inhibitor-1, Tissue Plasminogen Activator and Serum Lipoprotein(a) After Reperfusion Therapy in Acute Myocardial Infarction: Comparison Between Sequential and Director Percutaneous Transluminal Coronary Angioplasty*, Cardiology, Vol. 86, 1995, pp. 407-410	
	16	Stringer et al., *Plasminogen Activator Inhibitor-1 Released From Activated Platelets Plays a Key Role in Thrombolysis Resistance: Studies With Thrombi Generated in the Chandler Loop*, Arteriosclerosis and Thrombosis, Vol. 14, No. 9, September 1994, pp. 1452-1458	
	17	Gram et al., *Multicentre Evaluation of Commercial Kit Methods: Plasminogen Activator Inhibitor Activity*, Thrombosis and Haemostatis, Vol. 70, No. 5, 1993, pp. 852-857	
	18	Ogawa et al., *Difference in Plasminogen Activator Inhibitor Activity Between Non-Q-Wave Infarction and Q-Wave Infarction*, International Journal of Cardiology, Vol. 41, 1993, pp. 201-208	
	19	Sakamoto et al., *Association of Patency of the Infarct-Related Coronary Artery With Plasma Levels of Plasminogen Activator Inhibitor Activity in Acute Myocardial Infarction*, The American Journal of Cardiology, Vol. 70, No. 3, August 1, 1992, pp. 271-276	
	20	Levi et al., *Inhibition of Plasminogen Activator Inhibitor-1 Activity Results in Promotion of Endogenous Thrombolysis and Inhibition of Thrombus Extension in Models of Experimental Thrombosis*, Circulation, Vol. 85, No. 1, January 1992, pp. 305-312	
	21	Lijnen et al., *On the Reversible Interaction of Plasminogen Activator Inhibitor-1 With Tissue-Type Plasminogen Activator and With Urokinase-Type Plasminogen Activator*, The Journal of Biological Chemistry, Vol. 266, No. 7, March 5, 1991, pp. 4041-4044	
CF	22	Preissner et al., *Identification and Partial Characterization of Platelet Vitronectin: Evidence for Complex Formation With Platelet-Derived Plasminogen Activator Inhibitor-1*, Blood, Vol. 74, No. 6, November 1, 1989, pp. 1989-1996	

Examiner Signature		Date Considered	
	GFoster	1/5/06	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute form 1449A/PTO			Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Application Number	10/049,727
			Filing Date	06/25/2002
			First Named Inventor	Yahia Gawad
			Group Art Unit	1641
(use as many sheets as necessary)			Examiner Name	Gailene Gabel
Sheet	2	of	Attorney Docket Number	3477-931

	23	Wagner et al., *Interaction Between Plasminogen Activator Inhibitor Type 1 (PAI-1) Bound to Fibrin and Either Tissue-Type Plasminogen Activator (t-PA) or Urokinase-Type Plasminogen Activator (u-PA)*, J. Clin. Invest., Vol. 84, August 1989, pp. 647-655	
	24	Amiral et al., *Measurement of tPA and tPA - PAI-1 Complexes by Elisa, Using Monoclonal Antibodies: Clinical Relevance*, Thrombosis Research, Supplement VIII: 1988, pp. 99-113	
	25	Francis, Jr. et al., *Impaired Fibrinolysis in Coronary Artery Disease*, American Heart Journal, Vol. 115, No. 4, April 1988, pp. 776-780	
	26	Urdén et al., *Immunological Relationship Between Plasminogen Activator Inhibitors From Different Sources*, Thrombosis and Haemostatis, Vol. 57, No. 1, 1987, pp. 29-34	
	27	Verheijen et al., *Quantitative Analysis of the Composition of Mixtures of On-Chain and Two-Chain Tissue-Type Plasminogen Activator With a Spectrophotometric Method*, Thrombosis Research, Vol. 39, 1985, pp. 281-288	
	28	Hamsten et al., *Increased Plasma Levels of Rapid Inhibitor of Tissue Plasminogen Activator in Young Survivors of Myocardial Infarction*, The New England Journal of Medicine, Vol. 313, No. 25, December 19, 1985, pp. 1557-1563	

Examiner Signature	Ghosh	Date Considered	1/6/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.